Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

9.9%

7 terminated/withdrawn out of 71 trials

Success Rate

80.6%

-5.9% vs industry average

Late-Stage Pipeline

13%

9 trials in Phase 3/4

Results Transparency

10%

3 of 29 completed trials have results

Key Signals

18 recruiting3 with results7 terminated

Enrollment Performance

Analytics

Phase 2

45(73.8%)

Phase 3

7(11.5%)

Phase 1

5(8.2%)

N/A

2(3.3%)

Phase 4

2(3.3%)

61Total

Phase 2(45)

Phase 3(7)

Phase 1(5)

N/A(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (71)

Showing 20 of 71 trials

NCT07110038Phase 2Recruiting

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

Role: lead

NCT03081143Phase 2Active Not Recruiting

Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy

Role: lead

NCT05798156Phase 2Active Not Recruiting

Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Role: lead

NCT05393674Phase 2Completed

Fedratinib in Combination With Nivolumab

Role: lead

NCT07507968Phase 2Not Yet Recruiting

TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma

Role: lead

NCT06178445Phase 2Active Not Recruiting

Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer

Role: lead

NCT04351256Phase 2Completed

Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy

Role: lead

NCT07260175Phase 2Recruiting

Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma

Role: lead

NCT03753659Phase 2Completed

IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)

Role: lead

NCT06731803Phase 1Recruiting

Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma

Role: lead

NCT06981325Phase 2Recruiting

Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients

Role: lead

NCT05689671Phase 4Active Not Recruiting

Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma

Role: collaborator

NCT04318938Phase 2Active Not Recruiting

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Role: lead

NCT03252938Phase 1Active Not Recruiting

Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors

Role: lead

NCT04522544Phase 2Recruiting

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Role: lead

NCT05460000Phase 2Recruiting

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

Role: collaborator

NCT04122872Recruiting

GISAR German Interdisciplinary Sarcoma Registry

Role: lead

NCT07365930Recruiting

NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy

Role: lead

NCT05489250Terminated

The PLATON Network

Role: lead

NCT07387198Phase 2Not Yet Recruiting

Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab

Role: lead